Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adastra Pharmaceuticals

Request full access

Oral multi-kinase inhibitor development for oncology treatments

San Diego, United StatesHealth

About Adastra Pharmaceuticals

Adastra Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer. The company was founded in 2005, formerly known as Tragara Pharmaceuticals, and was acquired by Percans Oncology in September 2021. In January 2019, the company changed its name to Adastra Pharmaceuticals and appointed Scott Megaffin as CEO.

Adastra's lead product candidate is zotiraciclib (formerly TG02), an oral, multi-kinase inhibitor designed to treat glioblastoma multiforme (GBM), a type of aggressive brain cancer. Zotiraciclib functions as a potent cyclin-dependent kinase 9 (CDK9) inhibitor that can cross the blood-brain barrier. Its mechanism involves depleting key antiapoptotic proteins like Mcl-1 and Myc, which are crucial for cancer cell survival. The company has conducted clinical trials in collaboration with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). A Phase 1b clinical trial, completed in early 2021, investigated zotiraciclib in combination with temozolomide (TMZ) for patients with recurrent high-grade gliomas. The trial met its primary endpoint for progression-free survival and demonstrated that zotiraciclib was well-tolerated, showing particular benefit in patients with IDH-mutated tumors. Following these positive results, Adastra had planned a registration-enabling study.

In September 2021, Cothera Bioscience acquired the exclusive worldwide rights to zotiraciclib. This strategic acquisition allows Cothera to continue the development of the drug, building on the clinical data and regulatory groundwork established by Adastra. Before the acquisition, Adastra had raised a total of $87.6M in funding over several rounds from investors including Domain Associates, Morgenthaler Ventures, and Mitsubishi International.

Source: Dealroom company data

At a glance

Headquarters
San Diego, United States
Sector
Health

Adastra Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Adastra Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Domain Associates
  • ProQuest Investments
  • Oxford Bioscience Partners
  • Morgenthaler Ventures
  • RMI Partners
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Adastra Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adastra Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.